F M Investments LLC reduced its position in Haemonetics Co. (NYSE:HAE - Free Report) by 48.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 52,339 shares of the medical instruments supplier's stock after selling 50,133 shares during the period. F M Investments LLC owned about 0.10% of Haemonetics worth $4,087,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently made changes to their positions in HAE. Norges Bank acquired a new stake in shares of Haemonetics in the 4th quarter valued at $32,803,000. Groupama Asset Managment bought a new stake in shares of Haemonetics during the 4th quarter worth about $19,520,000. Raymond James Financial Inc. acquired a new position in shares of Haemonetics during the 4th quarter valued at about $19,002,000. Thrivent Financial for Lutherans raised its stake in shares of Haemonetics by 14.9% in the 4th quarter. Thrivent Financial for Lutherans now owns 1,264,294 shares of the medical instruments supplier's stock valued at $98,716,000 after acquiring an additional 164,111 shares in the last quarter. Finally, Boston Partners raised its stake in shares of Haemonetics by 27.5% in the 4th quarter. Boston Partners now owns 536,262 shares of the medical instruments supplier's stock valued at $41,485,000 after acquiring an additional 115,506 shares in the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of equities research analysts have issued reports on the company. Bank of America cut Haemonetics from a "neutral" rating to an "underperform" rating and decreased their target price for the stock from $95.00 to $68.00 in a research report on Friday, February 7th. Needham & Company LLC lowered their target price on shares of Haemonetics from $108.00 to $104.00 and set a "buy" rating on the stock in a research note on Tuesday, March 18th. JMP Securities cut their target price on shares of Haemonetics from $125.00 to $100.00 and set a "market outperform" rating for the company in a research report on Friday, February 7th. StockNews.com downgraded Haemonetics from a "buy" rating to a "hold" rating in a research report on Saturday, February 15th. Finally, Barrington Research lowered their price objective on shares of Haemonetics from $108.00 to $95.00 and set an "outperform" rating on the stock in a research note on Friday, February 7th. One research analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $101.22.
Get Our Latest Analysis on HAE
Haemonetics Stock Performance
Shares of NYSE HAE traded down $1.15 during trading hours on Tuesday, reaching $58.27. The stock had a trading volume of 572,832 shares, compared to its average volume of 687,585. The company has a market cap of $2.93 billion, a price-to-earnings ratio of 22.94, a PEG ratio of 1.11 and a beta of 0.41. Haemonetics Co. has a twelve month low of $55.30 and a twelve month high of $97.97. The business's fifty day moving average is $63.36 and its two-hundred day moving average is $73.29. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.55.
Haemonetics (NYSE:HAE - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. As a group, research analysts expect that Haemonetics Co. will post 4.55 EPS for the current year.
Haemonetics Profile
(
Free Report)
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.
See Also
Before you consider Haemonetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haemonetics wasn't on the list.
While Haemonetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
